Thank you Tricia for repeating my point about Her2 breast cancer.
Actually medicine is making good progress for other types of breast cancer. Subgroups are being divided out of the triple negative (3Ns) into low Her2 expressors, and are in trials for Herceptin, and the E75 vaccine.
Here is a partial list of ongoing clinical trials for 3Ns:
http://www.tnbcfoundation.org/clinicaltrials_prev.htm
and some ongoing studies . .
http://www.clinicaltrials.gov/ct2/re...ancer&no_unk=Y
I'm sure some of the science will go sideways into treating subgroups of we Her2 3+ (high Her2 expressors).
My guesses on progressing don't add up to the 39,620 number who died from breast cancer in 2013. It makes me go hmmmm. . . I'm about 8,000 short. Maybe some numbers come in from women who recur after 5 years, but that should be not be very high.
I'm certainly not making my living from statistics . . .